Literature DB >> 6698888

Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065.

J P McGovren, G L Clarke, E A Pratt, T F DeKoning.   

Abstract

It was previously shown that the potent new DNA-binding antibiotic, CC-1065, prolonged life span, but was not curative, when administered to mice bearing a variety of transplantable tumors. In this paper we show results of preliminary studies indicating that CC-1065 caused lethal delayed hepatotoxicity at therapeutic antineoplastic doses. In non-tumor-bearing mice toxic deaths were delayed ca 50 days after a single iv dose of 12.5 micrograms/kg and as much as 70 days after 10 micrograms/kg was given ip. Intravenous mouse LD50's were 9 micrograms/kg, single dose, and 0.3 microgram/kg/day, five daily doses. Intraperitoneal LD50's were 0.53 approximately 6.90 micrograms/kg, single dose, and 0.14 microgram/kg/day, five daily doses. Mice treated with high doses iv died within 12 days with frank hepatic necrosis, whereas delayed deaths at lower doses were associated with changes in hepatic mitochondrial morphology. This suggested that separate mechanisms of hepatotoxicity were operative at high and low dose ranges. Attempts to prevent the delayed toxicity of CC-1065 in the mouse by treatment with WR-2721, N-acetylcysteine, phenobarbital, Aroclor 1254, and 3-methylcholanthrene were unsuccessful; no effect on the LD50 or the times of death was observed. Lethal doses in the rabbit were similar on a body surface area basis to those in the mouse; evidence of hepatotoxicity was also observed in the rabbit.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6698888     DOI: 10.7164/antibiotics.37.63

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  16 in total

1.  In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Hightower; R Ramos; D Donato; M Penalver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065.

Authors:  D L Walker; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.

Authors:  B J Foster; P M LoRusso; E Poplin; M Zalupski; M Valdivieso; A Wozniak; L Flaherty; D A Kasunic; R H Earhart; L H Baker
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065.

Authors:  L H Li; R C Kelly; M A Warpehoski; J P McGovren; I Gebhard; T F DeKoning
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

5.  Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.

Authors:  George A Vielhauer; Megan Swink; Nikhil K Parelkar; James P Lajiness; Amanda L Wolfe; Dale Boger
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

6.  Structure and activity relationship of several novel CC-1065 analogs.

Authors:  L H Li; T L Wallace; T F DeKoning; M A Warpehoski; R C Kelly; M D Prairie; W C Krueger
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

7.  V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.

Authors:  R K Butryn; K S Smith; E G Adams; I Abraham; J Stackpole; K E Sampson; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.

Authors:  B K Bhuyan; K S Smith; E G Adams; T L Wallace; D D Von Hoff; L H Li
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.

Authors:  K S Smith; B A Folz; E G Adams; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug.

Authors:  Yuqiang Wang; Huiling Yuan; Susan C Wright; Hong Wang; James W Larrick
Journal:  BMC Chem Biol       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.